__NUXT_JSONP__("/drugs/Axalimogene_Filolisbac", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1587258-09-0",chebiId:b,chemicalFormula:b,definition:"A cancer vaccine containing a live-attenuated strain of the bacterium Listeria monocytogenes (Lm) encoding human papillomavirus (HPV) type 16 E7 fused to a non-hemolytic listeriolysin O protein with potential immunostimulatory and antineoplastic activities. Upon vaccination with axalimogene filolisbac, Listeria expresses the HPV 16 E7 antigen and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV 16 E7. This may result in tumor cell lysis. In addition, the Listeria vector itself may induce a potent immune response. HPV 16 E7, a cell surface glycoprotein and tumor associated antigen, is overexpressed in the majority of cervical cancer cells.",fdaUniiCode:"NY7PTD1862",identifier:"C74595",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C1663","C1920"],synonyms:["ADXS11-001","ADXS11-001 Vaccine","AXALIMOGENE FILOLISBAC","Attenuated Live Listeria Encoding HPV 16 E7 Vaccine","Attenuated Live Listeria Encoding Human Papilloma Virus 16 E7 Vaccine",c,"Lm-LLO-E7","Lovaxin-C"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FAxalimogene_Filolisbac",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Axalimogene_Filolisbac","","Axalimogene Filolisbac","2021-10-30T13:44:27.503Z")));